Healthcare / Medical Instruments & SuppliesKuala Lumpur
$0.81
+0.03 (+3.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-122.5M · quality 35.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.5B
P/E
40.3x
↑EV/EBITDA
N/A
•ROE
2.7%
↑Gross Margin
14.2%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-14.4%
FCF CAGR
—
FCF margin
4.6%
FCF / Net income
1.26x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.49B · net income $128.4M · FCF $161.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.49B | $3.49B | $2.51B | $2.26B | $5.57B |
| Net Income | $128.4M | $128.4M | $-18.3M | $-878.6M | $275.7M |
| EBITDA | $476.6M | $476.6M | $266.1M | $-544.7M | $711.0M |
| EPS | 0.01 | 0.01 | -0.01 | -0.12 | 0.03 |
| Gross Margin | 14.2% | 14.2% | 10.6% | 2.8% | 17.1% |
| Operating Margin | 0.6% | 0.6% | -7.7% | -23.6% | 5.3% |
| Net Margin | 3.7% | 3.7% | -0.7% | -38.9% | 4.9% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.07 | 0.10 | 0.06 |
| Current Ratio | 2.69 | 2.69 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $161.8M | $161.8M | $-122.5M | $-244.1M | $-778.3M |
| Returns | |||||
| ROE | 2.7% | 2.7% | -0.3% | -14.9% | 4.1% |
| Valuation | |||||
| P/E | 40.25 | 40.25 | — | — | 28.55 |
| EV/EBITDA | — | — | 28.82 | — | 9.20 |
| P/B | — | — | 1.30 | 1.11 | 0.95 |
| Growth & Yield | |||||
| Revenue Growth | 38.9% | 38.9% | 11.4% | -59.5% | — |
| EPS Growth | 261.7% | 261.7% | 93.0% | -509.6% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
76.0%
EPS terminal req.
$0.07
Spread vs growth
185.7%
5Y implied EPS CAGR
45.8%
EPS terminal req.
$0.09
Spread vs growth
215.9%
10Y implied EPS CAGR
26.7%
EPS terminal req.
$0.14
Spread vs growth
235.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-0.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → 0.01
Residual
-0.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.